Kimberly Gentile - 05 Jan 2026 Form 4 Insider Report for Biohaven Ltd. (BHVN)

Role
SVP, Clinical Operations
Signature
/s/ George Clark, Attorney-in-Fact
Issuer symbol
BHVN
Transactions as of
05 Jan 2026
Net transactions value
-$19,423
Form type
4
Filing time
07 Jan 2026, 21:34:08 UTC
Previous filing
07 Jan 2025
Next filing
03 Mar 2026
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Gentile Kimberly SVP, Clinical Operations C/O BIOHAVEN LTD., 215 CHURCH STREET, NEW HAVEN /s/ George Clark, Attorney-in-Fact 07 Jan 2026 0001704186

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction BHVN Common Shares Options Exercise $0 +3,750 +3.8% $0.000000 101,513 05 Jan 2026 Direct
transaction BHVN Common Shares Tax liability $19,423 -1,956 -1.9% $9.93 99,557 05 Jan 2026 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction BHVN Restricted Share Unit Award Options Exercise $0 -3,750 -33% $0.000000 7,500 05 Jan 2026 Common Shares 3,750 Direct F2, F3, F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 No shares were sold - these shares were withheld by the Issuer to satisfy tax withholding requirements in connection with the vesting of restricted share units.
F2 Each restricted share unit represents the contingent right to receive one common share of the Issuer.
F3 The reporting person was granted 15,000 restricted share units on January 5, 2025, vesting in four equal installments on January 5, 2025, 2026, 2027 and 2028, subject to the reporting person's continued service with the Issuer at each vesting date.
F4 Not applicable.